After the close of trading on the day, Medrex announced that it would be re-marketing ``MRX-5LBT,'' a post-herpetic nerve pain treatment drug jointly developed in the United States with De Western Therapeutics Institute.</p> The target review completion date (PDUFA date) based on the Prescription Drug User Fee Act*2 has been set as September 24, 2025 (US time). . There are also excellent topical patches that use less lidocaine and have the same efficacy. There's no way to get out. However, the stock price may go up because it becomes a rigged stock. But it will go down soon. It's a trick.
Jussie Smollett’s conviction overturned Main Stream Videos
